• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia.

作者信息

Tefferi Ayalew, Gangat Naseema, Wolanskyj Alexandra

出版信息

Blood. 2007 May 1;109(9):4105. doi: 10.1182/blood-2007-01-066985.

DOI:10.1182/blood-2007-01-066985
PMID:17449801
Abstract
摘要

相似文献

1
The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia.真性红细胞增多症中白细胞增多与其他血栓形成危险因素之间的相互作用。
Blood. 2007 May 1;109(9):4105. doi: 10.1182/blood-2007-01-066985.
2
Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia.白细胞增多症与诊断时的血栓形成有关，而JAK2 V617F突变与原发性血小板增多症病程中的血栓形成有关。
Int J Hematol. 2008 May;87(4):446-448. doi: 10.1007/s12185-008-0080-9.
3
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.白细胞增多是原发性血小板增多症中血栓形成的一个危险因素：与治疗、标准危险因素及Jak2突变状态的相互作用。
Blood. 2007 Mar 15;109(6):2310-3. doi: 10.1182/blood-2006-09-046342. Epub 2006 Nov 16.
4
Leukocytosis and risk stratification assessment in essential thrombocythemia.原发性血小板增多症中的白细胞增多及风险分层评估
J Clin Oncol. 2008 Jun 1;26(16):2732-6. doi: 10.1200/JCO.2007.15.3569. Epub 2008 Apr 28.
5
Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment.雌激素孕激素治疗期间伴有内脏血栓形成的jak2 val617phe阳性原发性血小板增多症的证据。
Blood Coagul Fibrinolysis. 2008 Jul;19(5):453-7. doi: 10.1097/MBC.0b013e3283079e46.
6
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.钙网蛋白突变不会改变1150例原发性血小板增多症患者中用于预测血栓形成风险的IPSET评分。
Blood. 2014 Oct 16;124(16):2611-2. doi: 10.1182/blood-2014-08-596676.
7
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia.白细胞增多症是年轻的真性红细胞增多症和原发性血小板增多症患者复发性动脉血栓形成的一个危险因素。
Am J Hematol. 2010 Feb;85(2):97-100. doi: 10.1002/ajh.21593.
8
The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.真性红细胞增多症中JAK2V617F突变及白细胞增多与血栓形成事件的关联
Exp Hematol. 2007 Nov;35(11):1704-7. doi: 10.1016/j.exphem.2007.08.011. Epub 2007 Oct 17.
9
Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.骨髓增殖性疾病中的白细胞增多、JAK2V617F突变与止血
Pathophysiol Haemost Thromb. 2008;36(3-4):148-59. doi: 10.1159/000175153. Epub 2009 Jan 27.
10
Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms.费城染色体阴性慢性骨髓增殖性肿瘤中白细胞增多与血栓形成的相关性。
Ann Hematol. 2009 Oct;88(10):967-71. doi: 10.1007/s00277-009-0706-x. Epub 2009 Feb 13.

引用本文的文献

1
Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms.中性粒细胞在慢性骨髓增殖性肿瘤血栓形成中的新作用。
Int J Mol Sci. 2021 Jan 24;22(3):1143. doi: 10.3390/ijms22031143.
2
Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.欧洲特发性血小板增多症的治疗：一项前瞻性长期观察性研究，纳入了 3649 例评估安纳格雷尔疗效和长期安全性研究中的高危患者。
Haematologica. 2018 Jan;103(1):51-60. doi: 10.3324/haematol.2017.174672. Epub 2017 Oct 27.
3
Eosinophilic biomarkers for detection of acute exacerbation of chronic obstructive pulmonary disease with or without pulmonary embolism.
用于检测伴或不伴肺栓塞的慢性阻塞性肺疾病急性加重的嗜酸性粒细胞生物标志物。
Exp Ther Med. 2017 Oct;14(4):3198-3206. doi: 10.3892/etm.2017.4876. Epub 2017 Aug 2.
4
Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants.癌症相关静脉血栓栓塞症：新型抗凝药物时代的治疗与预防更新。
Front Cardiovasc Med. 2016 Jul 28;3:24. doi: 10.3389/fcvm.2016.00024. eCollection 2016.
5
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.在世界卫生组织分类的原发性血小板增多症中，比较阿那格雷与羟基脲：ANAHYDRET 研究，一项随机对照试验。
Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11.
6
Biomarkers of deep venous thrombosis.深静脉血栓形成的生物标志物。
J Thromb Thrombolysis. 2012 Oct;34(3):335-46. doi: 10.1007/s11239-012-0721-y.
7
Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.血小板增多症：诊断评估、血栓形成风险分层及基于风险的管理策略
Thrombosis. 2011;2011:536062. doi: 10.1155/2011/536062. Epub 2011 Jun 8.
8
Assessing risk of venous thromboembolism in the patient with cancer.评估癌症患者静脉血栓栓塞的风险。
J Clin Oncol. 2009 Oct 10;27(29):4839-47. doi: 10.1200/JCO.2009.22.3271. Epub 2009 Aug 31.
9
Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?原发性血小板增多症和真性红细胞增多症中血栓形成的观点：白细胞增多是一个致病因素吗？
Blood. 2009 Jul 23;114(4):759-63. doi: 10.1182/blood-2009-02-206797. Epub 2009 Apr 16.
10
Development and validation of a predictive model for chemotherapy-associated thrombosis.化疗相关性血栓形成预测模型的开发与验证
Blood. 2008 May 15;111(10):4902-7. doi: 10.1182/blood-2007-10-116327. Epub 2008 Jan 23.